Top Markets
Coin of the day
Exopharm Limited Exopharm Limited

Exopharm Limited

EX1
株式のランク #39131
Exopharm Limited is an Australian clinical-stage firm dedicated to developing... Exopharm Limited is an Australian clinical-stage firm dedicated to developing groundbreaking therapeutics utilizing extracellular vesicles (EVs). Its core technologies include an extracellular vesicle positioning system (EVPS), which facilitates the precise targeting of exosomes by attaching specific molecules to their surface, guiding them to particular tissues or cell types. Another innovation is oligonucleotide packing, designed to optimize therapeutic delivery by preferentially loading specific RNA molecules into exosomes as medicinal cargo. Additionally, Exopharm employs ligand-based exosome affinity purification for effectively isolating and refining exosomes from biological fluids such as blood and cell culture media. The company's engineered EV product portfolio features Fortrexo CoV, aimed at treating SARS-CoV-2 infections; Cognevo, developed for neurodegenerative diseases; and PlexoDox, intended for cancer treatment. Exopharm Limited also maintains a research collaboration with Showa Denko Materials Co., Ltd. The company was founded in 2013 and is headquartered in Melbourne, Australia.
株価
$0.00700343
最終同期: 2023-10-30
時価総額
$637.31K
変化(1日)
0.50%
変化(1年)
0.00%
AU
取引 Exopharm Limited (EX1)

カテゴリー

Exopharm Limited(EX1)の配当利回りの履歴
Exopharm Limited(銘柄コード: EX1)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Exopharm Limited(EX1)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)